medi-cal glp-1 coverage for weight loss drugs changing California's Proposal to Cut GLP-1

Karen Basbaum, Chief Business Officer Number Of Employees: ~63 Stage: Publicly traded Financial Snapshot: The market cap for July 2026 is $2.81 billion

For example, subcutaneous semaglutide for diabetes (Ozempic) typically starts at 0.25 mg weekly for four weeks before increasing to 0.5 mg, with further increases only if needed

Tirzepatide (Mounjaro): Also once weekly, despite its dual action on GLP-1 and GIP receptors

As the gut contains ICC and enteric stem cells, targeting residual stem cells or transplantation of stem cells is a new area that needs further exploration [53]

In many instances, you and a healthcare professional may determine that the benefits outweigh the risks